<SEC-DOCUMENT>0001628280-24-023035.txt : 20240514
<SEC-HEADER>0001628280-24-023035.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240514060917
ACCESSION NUMBER:		0001628280-24-023035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		24941331

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rmti-20240514.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:320bb0de-23cc-4777-88f3-e8461214ebc5,g:0da53f95-f9fe-4e29-b97b-3c547ea46ca3,d:d68102b07996421692d407abf08f507c-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmti-20240514</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20240514.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id68102b07996421692d407abf08f507c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 14, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-23661</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">30142 S. Wixom Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Wixom</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Michigan</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">48393</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">248</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">960-9009</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"/><td style="width:7.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:427.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"/><td style="width:7.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:427.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:7.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:7.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title&#160;of&#160;Each&#160;Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading&#160;Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2024, Rockwell Medical, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8&#8209;K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following exhibit is being furnished herewith:</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT&#160;INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rmtiq124earningspr-final.htm">Press Release dated May 14, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROCKWELL MEDICAL,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 14, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rmtiq124earningspr-final.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3a0b165a9baf4600943c607ddb318768_1"></div><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%;padding-left:13.8pt">Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023.</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%;padding-left:13.8pt">Reports record gross profit of $3.1 million for the first quarter of 2024, an increase of 18% over the same period in 2023. </font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%;padding-left:13.8pt">Raises guidance for net sales, gross profit, and profitability on an adjusted EBITDA basis for the full-year 2024. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Wixom, Michigan, May 14, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; Rockwell Medical, Inc. (the &#34;Company&#34;) (Nasdaq&#58; RMTI), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, today announced financial and operational results for the three months ended March 31, 2024. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#34;We continue to see increasing interest in, and market demand for, our hemodialysis portfolio of products from medical equipment suppliers and distributors, along with health systems, dialysis centers, and skilled nursing facilities, domestically and internationally, all of which advances our vision to expand our global footprint and become the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">leading global supplier of all hemodialysis concentrates,&#34; said Mark </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Strobeck, Ph.D., Rockwell Medical&#8217;s President and CEO. &#34;Taking into account our first quarter 2024 financial and operating results, we are pleased to announce that we have revised our guidance for 2024 upward and believe we are well-positioned to deliver on that guidance.&#34; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">FIRST QUARTER 2024 FINANCIAL HIGHLIGHTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Net sales for the three months ended March 31, 2024 consisted solely of concentrates products sales. Net sales for the three months ended March 31, 2023 consisted of sales of concentrates products and the recognition of $1.5 million of deferred license revenue related to the termination of the Baxter distribution agreement. The following first quarter year-over-year financial highlights illustrate the organic growth driven exclusively by the Company's hemodialysis concentrates products, particularly after excluding the impact of deferred revenue recognized in the first quarter of 2023.  </font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:13.8pt">Net sales for the three months ended March 31, 2024 were $22.7 million, the highest quarterly concentrates products sales generated to date for the Company. This represents a 15% increase over net sales of $19.7 million for the same period in 2023. Excluding deferred revenue, net sales for the first quarter of 2024 increased 25% over the same period in 2023.</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:13.8pt">Gross profit for the three months ended March 31, 2024 was $3.1 million, representing an 18% increase over $2.6 million for the same period in 2023. Excluding deferred revenue, gross profit of $3.1 million in the first quarter of 2024 nearly tripled from $1.1 million over the same period in 2023.</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:-13.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:13.8pt">Gross margin for the three months ended March 31, 2024 was 14%, representing an increase from 13% for the same period in 2023. Excluding deferred revenue, gross margin for the first quarter of 2024 approximately doubled from gross margin of 6% for the same period in 2023.</font></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:13.8pt">Net loss for the three months ended March 31, 2024 was $1.7 million, representing a slight improvement over a net loss of $1.8 million for the same period in 2023. Excluding deferred revenue, net loss for the first quarter of 2024 improved by $1.5 million over a net loss of $3.2 million for the same period in 2023. </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:13.8pt">Adjusted EBITDA for the three months ended March 31, 2024 was ($0.5) million. Seasonal items related to audit, payroll tax, and other public-company related expenses historically incurred in the first quarter drove the Company's Adjusted EBITDA to be slightly negative. The Company expects expenses to normalize for the remainder of 2024.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:13.8pt">Cash and cash equivalents and investments available-for-sale at March 31, 2023 was $8.6 million compared to cash and cash equivalents and investments available-for-sale of $10.9 million at December 31, 2023. The decrease in cash of approximately $2.3 million was driven by changes in working capital. At close-of-business May 9, 2024, our cash and cash equivalents and investments available for sale was $10.2 million.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:13.8pt">During the first quarter of 2024, the Company amended its Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP. Under the terms of the amendment, Rockwell Medical reduced the interest rate on the $8.0 million remaining balance of the loan and extended the loan maturity date from March 2025 to January 2029. The Company will now make interest-only payments through September 2026 and may extend the interest-only period through March 2027 if certain conditions are met.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br></font></div><div style="padding-left:65.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.435%"><tr><td style="width:1.0%"></td><td style="width:52.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In Millions, Except Per Share Amounts)</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;2023*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$           22.7&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$           19.7&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)  </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.15pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Net Loss per Share **</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$         (0.06)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$         (0.10)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EPS ***</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$         (0.02)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$         (0.05)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:133%"><br>    * Includes $1.5 million of deferred license revenue related to the termination of the Baxter distribution agreement. </font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:133%">  ** See Note 3 for more details related to Basic and Diluted Weighted Average Shares Outstanding on Form 10-Q filed May 14, 2024.<br>*** See reconciliation to GAAP financial measures in the tables below.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">FIRST QUARTER 2024 OPERATING HIGHLIGHTS</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Rockwell Medical was certified as a Great Place to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> for the second year in a row. This accreditation reflects the continued positive changes the Company has made over the last two years.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Rockwell Medical entered into new and expanded distribution agreements with BioNuclear and Atlantic Medical International (&#34;AMI&#34;), respectively. In the aggregate, these agreements are expected to generate approximately $1 million in annual revenues for the Company. BioNuclear specializes in the marketing of reagents, equipment and furniture for clinical laboratories, medical equipment and devices, vaccines for human consumption and supplies for hemodialysis and peritoneal dialysis. AMI is Bermuda's leading supplier of medical products and equipment for the acute and continuing care markets. </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Rockwell Medical entered into a product purchase agreement with one of the largest health systems in the Mountain West region of the United States. Under the terms of the agreement, Rockwell Medical will supply this health system with the Company's liquid and dry acid and bicarbonate hemodialysis concentrates, cleaning agents, hemodialysis concentrates mixers and any additional products offered by Rockwell Medical. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">GUIDANCE</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Rockwell updates its guidance as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial 2024 Guidance</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Updated 2024 Guidance</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-right:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Updated Expected <br>Improvement (%) over 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$84.0M to $88.0M </font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$90.0M to $94.0M </font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-right:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13% to 18% increase over $79.8 million in net product sales for 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gross Profit </font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12.0M to $14.0M </font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$13.0M to $15.0M</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-right:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49% to 72% increase over $8.7 million in gross profit for 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gross Margin </font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14% to 16%</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">unchanged</font></td><td colspan="3" style="border-left:1pt solid #6d6d6d;border-right:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4 to 6 percentage point increase over 10% in gross margin for 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #6d6d6d;border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="border-bottom:1pt solid #6d6d6d;border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">nill to $0.5M</font></td><td colspan="3" style="border-bottom:1pt solid #6d6d6d;border-left:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$0.5M to $1.0M </font></td><td colspan="3" style="border-bottom:1pt solid #6d6d6d;border-left:1pt solid #6d6d6d;border-right:1pt solid #6d6d6d;border-top:1pt solid #6d6d6d;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113% to 126% increase over ($3.9) million in adjusted EBITDA for 2023</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Rockwell Medical projects net sales to grow in the mid-to-high single digits in 2025 and beyond. Rockwell Medical projects gross margin in 2025 to be approximately 20% and reaching above 25% in 2026 and beyond. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:130%">CONFERENCE CALL AND WEBCAST DETAILS</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Date&#58;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;Tuesday, May 14, 2024</font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Time&#58;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;8&#58;00am ET</font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Live Number&#58;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;(888) 660-6347 &#47;&#47;&#160;(International) 1 (929) 201-6594</font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Conference Call ID&#58;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;4944610</font></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Webcast and Replay&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">www.RockwellMed.com&#47;Results</font></div><div style="padding-left:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Speakers&#58;</font></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Mark Strobeck, Ph.D. &#8212; President and Chief Executive Officer&#59; and </font></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:13.8pt">Jesse Neri &#8212; SVP, Finance.</font></div><div style="padding-left:36pt;padding-right:-13.5pt"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Format&#58;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;Discussion of first quarter 2024 financial and operational results followed by Q&#38;A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">NON-GAAP FINANCIAL MEASURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Rockwell Medical&#8217;s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), this press release also includes references to Adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to one-time severance costs, deferred revenue and inventory reserve amounts, if applicable for the periods presented. The Company has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.  In addition, the Company has excluded deferred revenue from first quarter calculations of net sales, gross profit, gross margin and net loss.  Each of these adjusted measures is a non-GAAP financial measure.  The Company has provided reconciliations to the GAAP measures at the end of this press release.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted EBITDA is a key measure used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget and to develop short- and long-term operating plans. The Company provides Adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical&#8217;s core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of Rockwell Medical&#8217;s business.  Adjusted net sales, gross profit, gross margin and net loss is used by Rockwell Medical to understand growth within its hemodialysis concentrates business by excluding a one-time item that is not indicative of its core operating performance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted EBITDA and adjusted net sales, gross profit, gross margin and net loss should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA and adjusted net sales, gross profit, gross margin and net loss as tools for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than the most directly comparable financial measures calculated in accordance with GAAP. When evaluating the Company&#8217;s performance, you should consider Adjusted EBITDA and adjusted net sales, gross profit, gross margin and net loss alongside other financial performance measures, including net loss </font></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and other GAAP results. Adjusted EBITDA is our best proxy for cash burn.  Adjusted net sales, gross profit, gross margin and net loss enable us to understand growth within our hemodialysis concentrates business by excluding a one-time item that is not indicative of our core operating performance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ABOUT ROCKWELL MEDICAL</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. (Nasdaq&#58; RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at freestanding outpatient dialysis centers, at hospital-based outpatient centers, at skilled nursing facilities, or in a patient&#8217;s home. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the largest supplier of liquid bicarbonate concentrates and the second largest supplier of acid and dry bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of all hemodialysis concentrates. Certified as a Great Place to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in 2023 and 2024, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell Medical is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Driven to Deliver Life-Sustaining Dialysis Solutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, visit www.RockwellMed.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws. Words such as, &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;can,&#34; &#34;would,&#34; &#34;develop,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;forecast,&#34; &#34;project,&#34; &#34;intend,&#34; &#34;look forward to,&#34; &#34;remain confident,&#34; &#8220;feel confident,&#8221; &#8220;guidance,&#8221; or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include (without limitation) statements regarding&#58; plans to expand our global footprint&#59; our expectations regarding normalizing our expenses&#59; the impact of our strategy on our top and bottom line&#59; growth in the hemodialysis concentrates market&#59; the growth of our business&#59; guidance for net sales, gross profit, gross margin and adjusted EBITDA. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the &#34;Risk Factors&#34; section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">###</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CONTACT&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Heather R. Hunter, </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">SVP, Chief Corporate Affairs Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">IR&#64;RockwellMed.com</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">Financial Tables Follow</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">###</font></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i3a0b165a9baf4600943c607ddb318768_51"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"></td><td style="width:59.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Dollars In Thousands)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents &#38; Investments available-for-sale</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,619&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,723&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,472&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,930&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,643&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Outstanding</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,556,474</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,463,673</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and common stock equivalents*</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,222,734</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,343,670</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Common stock and common stock equivalents&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,556,474</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,552,673</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants (pre-funded)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911,000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and pre-funded stock warrants</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,556,474</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,463,673</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock converted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,636</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,636</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876,031</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194,202</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,218</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984,484</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,196,268</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock and common stock equivalents</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,222,734</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,343,670</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i3a0b165a9baf4600943c607ddb318768_62"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"></td><td style="width:45.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.003%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Thousands, Except Shares and Per Share Amounts)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,&#160;2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,&#160;2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,676&#160;</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,668&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,612&#160;</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,069&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</font></td><td style="border-right:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776&#160;</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,325)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (Expense) Income </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Other Expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(406)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(323)</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,731)</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td style="border-left:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:2pt solid #D9D9D9;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,750)</font></td><td style="border-right:2pt solid #D9D9D9;border-top:2pt solid #D9D9D9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Net Loss per Share</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.06)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Weighted Average Shares Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-left:2pt solid #D9D9D9;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,327,204</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-left:2pt solid #D9D9D9;border-right:2pt solid #D9D9D9;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,359,940</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i3a0b165a9baf4600943c607ddb318768_73"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.269%"><tr><td style="width:1.0%"></td><td style="width:45.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation to GAAP Financial Measures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Thousands, Except Shares and Per Share Amounts)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,731)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,750)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(757)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,205)</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(506)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(982)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EPS</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.02)</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Weighted Average Shares Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,327,204</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,359,940</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i3a0b165a9baf4600943c607ddb318768_87"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.923%"><tr><td style="width:1.0%"></td><td style="width:51.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.778%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation to GAAP Financial Measures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Dollars in Thousands)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,676&#160;</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,668&#160;</font></td><td style="border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales excluding Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,676</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit excluding Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,064</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,731)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,750)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss excluding Deferred Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,731)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,222)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:24.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rmti-20240514.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:320bb0de-23cc-4777-88f3-e8461214ebc5,g:0da53f95-f9fe-4e29-b97b-3c547ea46ca3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20240514" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20240514">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20240514_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20240514_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rockwellmed.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rmti-20240514_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:320bb0de-23cc-4777-88f3-e8461214ebc5,g:0da53f95-f9fe-4e29-b97b-3c547ea46ca3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_2e4bcd58-e717-408a-84f9-376eb9ae9dd8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5dd897f2-efbe-4527-b1e1-33b472e51134_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fb66c985-04e9-4753-82e0-e6ea26cf163e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a36eabe3-ff39-43ff-ad37-9037314f5e08_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b2cc56ee-db6d-4e2e-ab67-78b8939dee84_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_458fb2bc-7983-4856-9e44-0df34a923d0c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_54456dd5-1b00-428d-beaa-5e00e4cf87ff_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_af004c5d-cd00-421b-b63e-0b8ef601874e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6a6d741e-cb7b-4121-98e0-feec04d0e853_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e027fd87-da3d-45d7-bd00-546ce10fdd8d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cec6c2d9-51ad-4d54-99a3-86e44940bc06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_85298de8-c629-4577-9415-03e45fbe4f9c_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0f494637-499f-4f36-ac54-22b3c9ce02d6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_58eb53ef-fbee-4df8-932e-e8dce080a821_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a1f70ff8-89ee-46af-80b8-317b517cc044_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_93a1cc89-36ea-4e4a-819f-2abfdac32843_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8c6525cd-658f-48ce-b27f-41af90fec196_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f451a175-63d8-4c9c-99f4-0a957a67ef43_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2f17a412-d734-46bf-bffb-148455a1aa13_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1a3b98b2-4de1-427d-9448-0340e311fb62_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_332d16b0-c919-43f3-9be1-c65bf4c07efa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_aff94a97-1014-4705-ac51-54f1538d9a3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c5e0ef96-206c-460e-8f27-d18d113c8076_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rmti-20240514_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:320bb0de-23cc-4777-88f3-e8461214ebc5,g:0da53f95-f9fe-4e29-b97b-3c547ea46ca3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20240514.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_62d0543c-6d93-4c38-8d59-60cf45b7582f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_DocumentType_62d0543c-6d93-4c38-8d59-60cf45b7582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_af254780-d42b-434c-925e-77636acd3454" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_DocumentPeriodEndDate_af254780-d42b-434c-925e-77636acd3454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b6c2822c-3e4e-41bd-b4b6-eae3c8bd8d8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityRegistrantName_b6c2822c-3e4e-41bd-b4b6-eae3c8bd8d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d81eba6f-510c-40ec-b7fa-45f272e20957" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d81eba6f-510c-40ec-b7fa-45f272e20957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_88cb1dca-2409-4007-aec0-f96b24892f5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityFileNumber_88cb1dca-2409-4007-aec0-f96b24892f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1c29902f-ef9f-4946-a64d-50851c2f5037" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1c29902f-ef9f-4946-a64d-50851c2f5037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cf207848-f22d-4ff2-bd18-d3cf0698dc8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityAddressAddressLine1_cf207848-f22d-4ff2-bd18-d3cf0698dc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a7c803bc-9523-4ffc-9d4e-f56e7be99171" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityAddressCityOrTown_a7c803bc-9523-4ffc-9d4e-f56e7be99171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_417788bd-174c-4391-8854-0fdf27faddf4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityAddressStateOrProvince_417788bd-174c-4391-8854-0fdf27faddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_82968699-89c0-42d9-945b-ce67c8a576bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityAddressPostalZipCode_82968699-89c0-42d9-945b-ce67c8a576bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9c05488c-9bbb-4683-9542-29c7b288ea09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_CityAreaCode_9c05488c-9bbb-4683-9542-29c7b288ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1ccfa78f-4fca-40a0-8c2b-707f719a5605" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_LocalPhoneNumber_1ccfa78f-4fca-40a0-8c2b-707f719a5605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4795b702-642e-4354-abe0-d4ed53ca0155" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_WrittenCommunications_4795b702-642e-4354-abe0-d4ed53ca0155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d4c8c7ae-ba1d-4721-97bb-cd4e9af832e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_SolicitingMaterial_d4c8c7ae-ba1d-4721-97bb-cd4e9af832e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_58a71a03-09a8-4c47-8973-41a5b44384ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_PreCommencementTenderOffer_58a71a03-09a8-4c47-8973-41a5b44384ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_511fc163-2559-4daa-a4c1-b5794c105662" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_511fc163-2559-4daa-a4c1-b5794c105662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f2be1ca-bdba-4537-8aba-a87ea3a54902" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_Security12bTitle_6f2be1ca-bdba-4537-8aba-a87ea3a54902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae6e7d22-5696-4dff-991c-7791dff4995c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_TradingSymbol_ae6e7d22-5696-4dff-991c-7791dff4995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8419df4a-5493-4dc0-bc3a-b5dc7f63b5fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_SecurityExchangeName_8419df4a-5493-4dc0-bc3a-b5dc7f63b5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_62bffc4f-a6ca-4ae5-b113-4674f1f51896" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityEmergingGrowthCompany_62bffc4f-a6ca-4ae5-b113-4674f1f51896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_acecb43d-dc47-4ac4-9471-1964c456876a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_EntityCentralIndexKey_acecb43d-dc47-4ac4-9471-1964c456876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a20ca598-6a12-471c-8a19-cbbe323f0b54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ccca6ea-9ada-415e-b076-e69367d7ff0c" xlink:to="loc_dei_AmendmentFlag_a20ca598-6a12-471c-8a19-cbbe323f0b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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MP6BCY#]*B:(C,6YDZQ&.WUF6O!G!.P\X03E!A!5LA-2Q6^F\#%;N'QU*]+J
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M:/CB\,N3E+@@&2*LWQCAW'1YV3Q(=6F9V>DM.ZI>?V7/COH*C=KQ6R E!9D
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M,=4]@B=FM::8(#HQ^$5B?:+($;[?$&7ZE>MT]H[@'5E<7%H'0Z=_1'F [N2
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M3QQNL4*B)J'R1VN1C6&(^S_^[!/B"&:F*4*ZK%7(5$>4EZF!1A+7<O.R*(A
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M[\<-6UM9*JJMSLYY <.)1I\F[UTT0?<0,I-&3L>XH45.$Z\?C9S>4$M+N&^
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M>&CX>A8"I$L4%P*><U(;7N[P,!I-\'D\YOGON66ND\@%G,P;R %8W:F9.TO
MR^HJ,6O%V6D4(X"LD^/@S.>$Y<"9YC#!+8XM+H_B!)I8'*$#_;)$(AG+<0^Q
M?U3>#/3<<.5CANVM0B JICLZO;9*[35J@U;FDP.>AOI"71Q*94.^O-U99 :,
M3!3U*2+Y7WRD%+%>GI8.;X[D^QVR[7T2TQK\7I1YN]@B#XJ0WKG-;Q-Q@3UF
MBPOU +>EU7M<1$[[MW_A).7("%/6S6[>H]2,]/3<O$QBQM6KS _F8W!N%>-
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MHC5LI'>GV? %4-F9$$TJC+&E:?=I!#R0?U0L,30)%S6Z)X$WS !AG-_I1T
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M*4EJ/2^/UB:?M $$! &):4+,QYF!;X9$4<@FEC127J[?Z80VH>Y,3,]V]8W
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A\DE)""0AD(1 $@+_?V=^N>D[9%*(     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139731460428384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142 S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<F]P<R]A<' N>&UL4$L! A0#%     @ )S&N6)<\P\+O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )S&N
M6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  G,:Y8G_OTUT $  !U$   &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )S&N
M6)^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  G,:Y8EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    "  G,:Y8JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ )S&N6"0>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ )S&N6&60>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rmti-20240514.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rmti-20240514.htm">rmti-20240514.htm</File>
    <File>rmti-20240514.xsd</File>
    <File>rmti-20240514_lab.xml</File>
    <File>rmti-20240514_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rmti-20240514.htm": {
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20240514",
   "dts": {
    "inline": {
     "local": [
      "rmti-20240514.htm"
     ]
    },
    "schema": {
     "local": [
      "rmti-20240514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20240514_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20240514_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "report": {
    "R1": {
     "role": "http://rockwellmed.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmti-20240514.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmti-20240514.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-023035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-023035-xbrl.zip
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MY[G,HS^0>:1',?\?'L)T>_S2Y<'+[4_BDSDZ?;%Y)5_]M<[3%_\#4$L#!!0
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M,JG"1_3IW\,I"LAP0H^6#]2,\M1"^C5= !T9D_83/4Q[<R(4VT\XG8TK?AR
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M:##\41@YL!BPMRXF<D(=?7$W>)6?!\Y+DQO=AFYIWS-Z(.W[%S;^!R,U7G0
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M&BC$,R%*Z>L P\!";O(FF3*UIYA2<2U^*K%6KDF@W'/H(*76OQ%KPE33$$M
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M[/3OT'K@-EUV4=41T$0>A!]$UU_Q95JE[WH5O$V<YJ^,W5?9+L#@ESP[2>^
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M/U!+ 0(4 Q0    ( "<QKEAD8+5M4 \  -I^   1              "  0
M  !R;71I+3(P,C0P-3$T+FAT;5!+ 0(4 Q0    ( "<QKEAJZ#&Y;@(  &T'
M   1              "  7\/  !R;71I+3(P,C0P-3$T+GAS9%!+ 0(4 Q0
M   ( "<QKEA;,=.O)0H  'U5   5              "  1P2  !R;71I+3(P
M,C0P-3$T7VQA8BYX;6Q02P$"% ,4    "  G,:Y8!FST-+ &  #<,   %0
M            @ %T'   <FUT:2TR,#(T,#4Q-%]P<F4N>&UL4$L! A0#%
M  @ )S&N6-E,1Q@4*0  OQ," !P              ( !5R,  ')M=&EQ,3(T
J96%R;FEN9W-P<BUF:6YA;"YH=&U02P4&      4 !0!. 0  I4P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>rmti-20240514_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20240514.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
